NCT05476354

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

A Randomized, Double-blind, Multicenter, Placebo-control, Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 271 (actual)
• Sponsor: Handok Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Irbesartan/Amlodipine low	Irbesartan/Amlodipine low once daily for 8 weeks
DRUG	Irbesartan/Amlodipine high	Irbesartan/Amlodipine high once daily for 8 weeks
DRUG	Irbesartan	Irbesartan once daily for 8 weeks

Timeline

• Start date: 2022-07-05
• Primary completion: 2023-04-03
• Completion: 2023-06-13
• First posted: 2022-07-27
• Last updated: 2023-08-18

Locations

1 site across 1 country: South Korea